Second, considering the great differences in the pathogenesis of primary and secondary osteoporosis, the therapeutic effects of IFN-γ need to be investigated by evaluating the dose, frequency, usage, and duration of IFN-γ treatment separately. Here, IFNG is linked to osteoporosis.